CN107149675A - A kind of new application of interleukin 12 - Google Patents
A kind of new application of interleukin 12 Download PDFInfo
- Publication number
- CN107149675A CN107149675A CN201610136868.3A CN201610136868A CN107149675A CN 107149675 A CN107149675 A CN 107149675A CN 201610136868 A CN201610136868 A CN 201610136868A CN 107149675 A CN107149675 A CN 107149675A
- Authority
- CN
- China
- Prior art keywords
- interleukin
- sag
- new application
- hepatitis
- inactivity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
The invention discloses a kind of new application of interleukin 12, it is characterized in that, the purposes that described interleukin 12 treats chronic hepatitis B inactivity Sag carrier's medicines as preparing；It is intended to widen the use scope of cytokine 12, while also providing new medicine for chronic hepatitis B inactivity Sag carrier.
Description
Technical field
It is a kind of hepatitis B table specifically the invention discloses a kind of new application of interleukin 12
The new application of face antigen vaccine.
Background technology
There are 2,000,000,000 population infection hepatitis Bs in the whole world, wherein 2.4 hundred million be chronic HBV surface antigen
(Sag) carrier.Chronic hepatitis B (CHB) some people is sluggish, but some people
Hepatic sclerosis, liver cancer can be caused.
In recent years, using interferon and nucleoside analogue treatment CHB, remarkable progress, Most patients are obtained
After treatment, the Cyklokapren of serum paddy third (ALT), HBVDNA, Beagle can recover in peripheral blood
It is normal or switch to Sag still lasting masculins in feminine gender, but peripheral blood, it is extremely difficult to serological conversion and (anti-H's is presented
It is positive).In these years, domestic and foreign scholars have proposed the concept that chronic hepatitis B feature is cured,
That is, treatment chronic hepatitis B except require ALT, HBVDNA, Beagle it is steady in a long-term normal with
Outside, still require that peripheral blood Sag is eliminated, and hepatitis B surface antibody, i.e. serum occur by the Sag positives turn
It is changed to feminine gender, and anti-H's occurs this is also terminal or target to treatment of chronic.Reach this mesh
Mark, is exactly that CHB features are cured.
The content of the invention
In view of the above-mentioned problems, being used as preparation treatment chronic type b it is an object of the invention to provide cytokine -12
The purposes of hepatitis non-active hepatitis B s antigen carries medicine, had both widened the use scope of cytokine -12,
New medicine is also provided for chronic hepatitis B non-active hepatitis B s antigen carries simultaneously.
In order to solve the above technical problems, the technical scheme that the present invention is provided is such：
A kind of new application of interleukin 12, described interleukin 12 is used as preparation treatment chronic
The purposes of type hepatitis non-active hepatitis B s antigen carries medicine.
It is preferred that, the new application of above-mentioned interleukin 12, described interleukin 12 joint HBsAg
Specific antigen epitope peptide treats the use of chronic hepatitis B non-active hepatitis B s antigen carries medicine as preparing
On the way.
It is preferred that, the new application of above-mentioned interleukin 12, described HBsAg specific antigen epitopes
Peptide is HBsAg specific antigen epitope p peptides.
It is preferred that, the new application of above-mentioned interleukin 12, described hepatitis B inactivity HBsAg
Carrier detction index is：HBsAg+, serum titer ＜ 1000IU/ml, HBeAg-, HBV-DNA-.
Compared with existing, technical scheme provided by the present invention uses interleukins
- 12 (interleukin-12, IL-12) are used as preparation treatment chronic hepatitis B non-active hepatitis B s antigen carries
It is chronic as treatment is prepared that medicine, particularly interleukin 12 combine HBsAg specific antigen epitopes peptide
The medicine of hepatitis B non-active hepatitis B s antigen carries, to treat chronic hepatitis B inactivity HBsAg
The treatment of carrier provides new medicine；And from the point of view of the result of pharmacodynamic experiment, to treating acute put
That penetrates disease has good effect.
Brief description of the drawings
Fig. 1 is that HBsAg specificity P peptides joint rhIL-12 induction human PBMCs s produces IFN-γ amount curve
Figure.
Embodiment
With reference to embodiment, the claim to the present invention is described in further detail, but not
Any limitation of the invention is constituted, any limited number of time done in the claims in the present invention protection domain
Modification, still within the claims of the present invention.
Experimental example 1
The mouse hepatitis B model set up using hydrodynamic(al) force method, HBV virus particles are injected from experiment mice tail vein
42 days afterwards, hepatitis B model is set up, peripheral blood continuous expression HBsAg is positive, and titre is in 50-200IU/ml.
HBsAg specificity P polypeptides (synthetic method) 1~30 μ g/ml；RhIL-12 0.5-4ng/ml, respectively or
Joint and the PBMC of Healthy People and Peripheral Blood in Patients with Chronic Hepatitis B are cultivated 72 hours, are collected and are detected supernatant
IFN-γ level (ELISA), as a result See Figure 1, points out HBsAg specificity P peptides joint rhIL-12 can be non-
A large amount of IFN-γs are significantly often induced, are conducive to promoting HBsAg serological conversions.
Experimental example 2
24, the mouse hepatitis B model set up using hydrodynamic(al) force method, to send out three groups, saline control group, IL-12
Group, P peptides joint rhIL-12 groups, IL-12 and P peptides are to be subcutaneously injected, and once in a week, totally three weeks, are stopped
Observation post administration 5 weeks, weekly observation experiment mouse peripheral blood HBsAg levels.
As a result show：HBsAg specificity P peptides joint IL-12, which has, significantly promotes HBsAg serological conversions to act on.
Above-described is only presently preferred embodiments of the present invention, all institutes in the range of the spirit and principles in the present invention
Any modifications, equivalent substitutions and improvements made etc., should be included in the scope of the protection.
Claims (4)
1. a kind of new application of interleukin 12, it is characterised in that described interleukin 12 conduct
Prepare the purposes for the treatment of chronic hepatitis B inactivity Sag carrier's medicines.
2. the new application of interleukin 12 according to claim 1, it is characterised in that described
Interleukin 12 combines Sag specific antigen epitopes peptide as preparation and treats chronic hepatitis B inactivity
The purposes of Sag carrier's medicines.
3. the new application of interleukin 12 according to claim 3, it is characterised in that described
Sag specific antigen epitopes peptide is Sag specific antigen epitope p peptides.
4. the new application of interleukin 12 according to claim 1 or 2, it is characterised in that institute
The hepatitis B inactivity Sag carrier detction indexs stated are：Sag+, serum titer ＜ 1000IU/ml,
Beagle-, HBV-DNA-.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610136868.3A CN107149675A (en) | 2016-03-10 | 2016-03-10 | A kind of new application of interleukin 12 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610136868.3A CN107149675A (en) | 2016-03-10 | 2016-03-10 | A kind of new application of interleukin 12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107149675A true CN107149675A (en) | 2017-09-12 |
Family
ID=59792311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610136868.3A Pending CN107149675A (en) | 2016-03-10 | 2016-03-10 | A kind of new application of interleukin 12 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107149675A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1636063A (en) * | 2001-11-01 | 2005-07-06 | 健方公司 | Genetic vaccine against human immunodeficiency virus |
| CN101361969A (en) * | 2008-01-29 | 2009-02-11 | 广州市恺泰生物科技有限公司 | Therapeutic hepatitis b vaccine and preparation method and use thereof |
| CN106581672A (en) * | 2015-10-15 | 2017-04-26 | 广东思峰生物科技有限责任公司 | RhIL-12 containing medicine composition for treating non-active hepatitis B |
-
2016
- 2016-03-10 CN CN201610136868.3A patent/CN107149675A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1636063A (en) * | 2001-11-01 | 2005-07-06 | 健方公司 | Genetic vaccine against human immunodeficiency virus |
| CN101361969A (en) * | 2008-01-29 | 2009-02-11 | 广州市恺泰生物科技有限公司 | Therapeutic hepatitis b vaccine and preparation method and use thereof |
| CN106581672A (en) * | 2015-10-15 | 2017-04-26 | 广东思峰生物科技有限责任公司 | RhIL-12 containing medicine composition for treating non-active hepatitis B |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sablan et al. | Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine | |
| Shah et al. | Long-term effectiveness of accelerated hepatitis B vaccination schedule in drug users | |
| Toporovski et al. | Interferons as potential adjuvants in prophylactic vaccines | |
| Yang et al. | Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy | |
| EP3025730A1 (en) | Viral immunotherapy drug complex and uses thereof | |
| Romano’ et al. | Hepatitis B vaccination: A historical overview with a focus on the Italian achievements | |
| CN101361969A (en) | Therapeutic hepatitis b vaccine and preparation method and use thereof | |
| Fabrizi et al. | Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population | |
| EP3515929A1 (en) | Hepatitis b therapeutic vaccines | |
| CN107149675A (en) | A kind of new application of interleukin 12 | |
| CN102268093A (en) | Fusion protein of hepatic-targeted peptide and human interferon a2b, and preparation method and application thereof | |
| CN107174659A (en) | A kind of novel drugs for treating chronic hepatitis B | |
| Lelie et al. | Immune Response to a Heat-Inactivated Hepatitis B Vaccine in Patients Undergoing Hemodialysis: Enhancement of the Response by Increasing the Dose of Hepatitis B Surface Antigen From 3 to 27 µg | |
| PH12020500194A1 (en) | Malaria vaccine | |
| Zhang et al. | Interleukin-24 limits tumor-infiltrating T helper 17 cell response in patients with hepatitis b virus-related hepatocellular carcinoma | |
| Chengalvala et al. | Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid | |
| Wiedermann et al. | Multicentre dose range study of a yeast-derived hepatitis B vaccine | |
| Aguilar et al. | Action mechanisms and scientific rationale of using nasal vaccine (HeberNasvac) for the treatment of chronic hepatitis B | |
| CN102199217B (en) | Hepatitis B virus multi-epitope fusion protein and preparation method and application thereof | |
| CN100503827C (en) | Hepatitis B virus vaccine synergistic protein and its gene | |
| CN1861191A (en) | Application of human sDR5 protein as medicine to treat virus hepatitis B | |
| CN1919341B (en) | Application of hepatitis B surface antigen-antibody complexes in preparing prophylaxis product with no response or low response to hepatitis B vaccine | |
| CN104056266B (en) | Mopterin adjuvant and the vaccine containing mopterin adjuvant | |
| Alam et al. | An unusual side effect of interferon alfa 2A: digital clubbing | |
| CN107149674A (en) | The purposes of IL-12 and flagellin in treatment chronic hepatitis B medicine is prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170912 |